Relapse-free survival of non-metastatic patients treated with primary androgen deprivation

Many patients with no specific evidence of metastatic disease now receive primary androgen deprivation therapy (PADT) much earlier than was the case before the availability of the PSA test. This includes patients who get hormone therapy for a rising PSA after other forms of first-line therapy and patients who receive hormone therapy as their first-line treatment. … READ MORE …

Hormone therapy effective in man with PSA > 21,000, but …

An article in just published in Onkologie reports the diagnosis and (short-term) treatment of widely disseminated, metastatic prostate cancer in a 64-year-old Croatian man with a PSA of > 21,000 ng/ml. … READ MORE …

Short-term ADT with RT for localized prostate cancer

The RTOG 94-08 clinical trial was designed to test the idea that just 4 months of hormone therapy, administered  before and during radiation therapy, would improved the overall survival of patients diagnosed with clinical stage T1b-T2b prostate cancer and a PSA level equal to or lower than 20 ng/ml. … READ MORE …

Prostate cancer news report: Sunday, January 24, 2010

In this weekend’s prostate cancer news reports, we have addressed recent publications on:

  • A SNP that may be specifically linked to risk for prostate cancer in African Americans
  • The need for extended biopsies in men with larger prostates who are considering focal treatment for prostate cancer
  • A possible association between diabetes, race, obesity, and risk for prostate cancer progression
  • Neoadjuvant hormone therapy, brachytherapy, and all cause mortality in older patients … READ MORE …

Prostate cancer news reports: Wednesday, January 13, 2010

Today’s news reports summarize papers recently published on:

  • Optimism, pessimism, and long-term health outcomes
  • External beam radiation + hormone therapy for high-risk patients
  • Quality of life and health utility after radical prostatectomy
  • Paclitaxel + estradiol combination therapy in men progressing after docetaxel-based chemotherapy … READ MORE …

Hormone therapy not helpful for low-risk patients receiving first-line radiation

A report presented yesterday in Chicago, at the annual meeting of the American Society for Radiation Oncology (ASTRO), suggests that short-term hormone therapy given prior to and during first-line radiation treatment to intermediate-risk prostate cancer patients increases their chance of living longer, compared to those who receive radiation alone. However, the same study also showed that there is no significant benefit for low-risk patients. … READ MORE …

Prostate cancer news reports: Wednesday, September 23, 2009

Today’s news reports cover items on:

  • Extent and number of biopsy cores and eligibility for active surveillance
  • Intermittent vs. complete androgen deprivation
  • Hormone therapy and risk for cardiovascular disease and death
  • Surrogate markets for disease progression in men with CRPC … READ MORE …

Get every new post delivered to your Inbox.

Join 1,455 other followers